Precede Biosciences

Precede Biosciences is at the forefront of biotechnology research, impacting precision medicine with a first-in-class liquid biopsy platform. Precede Biosciences is dedicated to addressing the significant gaps in accessing and understanding disease-defining biology, offering innovative solutions for medical and research communities. Their unique genome-wide platform profiles circulating chromatin and the DNA methylome, delivering high-resolution insights into the dynamic activity of individual genes and pathways in diseased tissues using just 1mL of plasma.

Located in Boston, MA, Precede Biosciences partners with developers of new medicines and advances its own diagnostic tests, working towards a world where new medicine development efforts succeed more frequently. Precede Biosciences envisions a future where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease. The company is committed to transforming healthcare through groundbreaking research and accessible diagnostic tools.

Precede Biosciences is revolutionizing the approach to disease understanding and treatment. By providing actionable, disease-defining transcriptional biology through a simple blood test, Precede Biosciences ensures that new medicines are developed effectively and that precise, personalized treatments are available to all. Discover how Precede Biosciences is making a difference in precision medicine and beyond.

We invite the manager of Precede Biosciences to create a customized and exclusive company showcase and product listing on our platform to further enhance your visibility and commercial opportunities.